As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Researchers sought to determine the occurrence of thrombotic events in a cohort of pediatric patients with myeloproliferative neoplasms.
Review highlights current approaches to risk stratification, differential diagnosis, and the optimal use of current treatment options for polycythemia vera.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Detection of driver mutations acquired very early in life and life-long clonal expansion may predict clinical outcomes and interventions for patients with myeloproliferative neoplasms.
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
An evaluation of more than 2 dozen types of integrative medicine therapies demonstrated that patients with MPNs who engaged in these activities had improved negative symptoms and quality of life.
